The underdiagnosis of Silent Heart Attacks (SHA) represents a critical market factor. Understanding the genuine predominance of SHAs and the factors adding to their silent nature is urgent for market examination. The size of the affected populace directly impacts the demand for indicative instruments and preventive measures, molding market elements.
The market is altogether impacted by headways in analytic advancements for SHAs. Advancements in electrocardiography (ECG), cardiac imaging, and blood biomarker examination add to more precise and early detection. Organizations putting resources into state-of-the-art demonstrative devices can gain an upper hand in this developing business sector.
The prevalence of risk factors for cardiovascular illnesses, including changeable factors like hypertension, diabetes, and heftiness, impacts market elements. Drives advancing preventive measures, way of life adjustments, and normal health check-ups add to early detection and management of SHAs.
The market for SHAs is molded by the advancement of far-reaching cardiac recovery projects and post-occasion care arrangements. Organizations focusing in on restoration treatments, way of life directing, and long-haul care add to further developed results for people who have encountered SHAs.
Pharmacological medicines, including antiplatelet agents, beta-blockers, and statins, assume an urgent part in overseeing SHAs. The market is affected by the advancement of effective and customized drug mediations that forestall further cardiovascular occasions. Continuous examination in this space impacts market growth and importance.
The skill of healthcare experts, particularly cardiologists and experts in interventional cardiology, is a basic market factor. Clinical experts add to precise determination and effective treatment arranging. Market players focusing in on joint efforts and training projects can improve the availability of consideration.
The ascent of telemedicine and remote observing innovations is impacting the SHA market. Organizations offering answers for distant patient checking, virtual discussions, and advanced health stages add to the developing landscape of post-SHA care and follow-up.
Market Synopsis of the Silent Heart Attack Market
Silent Heart Attack Market is anticipated to reach USD 11,720.07 Million by 2030 at 6.7% CAGR during the forecast period 2022-2030.Silent heart attack usually does not have any symptoms. The patient may experience chest pain, shortness of breath and cold sweats. It is mostly misunderstood as indigestion, nausea, and other common diseases. The silent heart attack is usually caused due to various factors such as smoking or chewing tobacco, high cholesterol, high blood pressure, diabetes, and obesity. Risk of silent heart attack increases with an increase among the diabetic population and people addicted to smoking. Various imaging tests such as Cardiac Computerized Tomography, Magnetic Resonance Imaging (MRI), electrocardiogram, echocardiogram, blood tests, and others.
According to the Center for Disease Control and Prevention (CDC), as of 2012, nearly half of all adults 117 million population in the U.S. had one or more chronic health conditions. One in four adults were diagnosed with two or more chronic health diseases. Cardiovascular diseases, and diabetes are increasing the economic burden of various developing and developed nations across the globe.
The Silent Heart Attack Market is driven by rising prevalence of chronic diseases such as cardiovascular diseases, diabetes, and others. Furthermore, changing lifestyle, and increasing demand for diagnosis devices for cardiovascular diseases. However, limited number of trained personnel has restrained the growth of market. However, high cost of diagnosis and treatment of cardiovascular diseases also restrains the growth of the market.
Market Segments
Silent Heart Attack Market is segmented on the basis of Diagnosis, Indication, Devices, and End User.
On the basis of diagnosis, market is segmented into cardiac computerized tomography, magnetic resonance imaging, electrocardiogram, echocardiogram, blood tests, and others.
On the basis of indication, the market is segmented into medications, coronary angioplasty and stenting, coronary artery bypass surgery, and others.
On the basis of end-user, the market is segmented into hospitals, clinics, diagnostic centers, and others.
Regional Analysis of the Silent Heart Attack Market
America accounts for the largest market for the silent heart attack. The increasing prevalence of cardiovascular diseases and diabetes is the major driving factor for the growth of the market. According to Center of Diseases Control and Prevention (CDC), 9.3% of the total America population is suffering from diabetes. Increasing diabetic and obese population, rising demand for the better treatment for the diseases and well developed infrastructure has provided fuel for the growth of the market. North America accounts for the major share in the American silent heart attack market.
Europe accounts for the second largest market due to a well-developed healthcare sector, continuously increasing patient population and high healthcare expenditure. Additionally, increasing prevalence of diabetes in the European Union (EU) also fuels the market growth. Germany, U.K and France hold the first, second and third position in the Silent Heart Attack Market.
Asia Pacific is expecting the fastest growth for this market. Increasing prevalence of cardiovascular diseases and rapid developments in the healthcare infrastructure are the major driving factors for the growth of the market. India and China are the two major regions with the highest contribution to the market growth owing to the highest diabetic population, and increasing presence of heart attack among these patients. Additionally, rising geriatric population further drive the growth of the market.
In the Middle East & Africa, the market is expected to show steady growth due to the evolving healthcare system, and increasing demand for diagnostic and treatment services. The Middle East is the major contributor for the market which is driven by the presence of well developed economies like Kuwait and Qatar. Whereas, Africa exhibits slow growth due to limited development in the field of medical science and presence of poor economic conditions in various developing regions of Africa.
Silent Heart Attack Market by Type, 2016 (%)
Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders
Key Players in the Silent Heart Attack Market
Some of the key players in Silent Heart Attack Market are Siemens (U.S.), Schiller AG, Midmark Corporation, Koninklijke Philips N.V. (Japan), Bionet (Korea), Welch Allyn (U.S.), Toshiba Medical Systems Corporation (Japan), AstraZeneca plc (U.K), Pfizer (U.S.), Sanofi (France), Merck & Co. (U.S.), Daiichi Sankyo Company Limited, Novartis AG (Germany), Bayer (Germany), Takeda Pharmaceutical Company Limited (Japan), Boehringer Ingelheim GmbH (Germany), Astellas Pharma Inc. (Japan), Johnson & Johnson (U.S.), United Therapeutics Corporation (U.S.), Actelion Pharmaceuticals Ltd. (Switzerland) and F. Hoffmann-La Roche Ltd (Switzerland).
Research Methodology
Intended Audience
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)